Form 8-A12B INTERPACE BIOSCIENCES,

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-A

 

 

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

PURSUANT TO SECTION 12(b) OR (g) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

 

Interpace Biosciences, Inc.

 

 

(Exact name of registrant as specified in its charter)

 

Delaware		22-2919486
(State or incorporation of organization)		(IRS Employer Identification No.)
Waterview Plaza, Suite 310, 2001 Route 46 Parsippany, NJ (855) 776-6419 (Address of Principal Executive Offices)		07054 (Zip Code)

 

Securities to be registered pursuant to Section 12(b) of the Act:

 

Title of each class to be so registered		Name of each exchange on which each class is to be registered
Common Stock, par value $0.01		The Nasdaq Stock Market LLC

 

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. ☒

 

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ☐

 

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐

 

Securities Act registration statement file number to which this form relates: 333-299123.

 

Securities to be registered pursuant to Section 12(g) of the Act: None.

 

 

 

INFORMATION REQUIRED IN REGISTRATION STATEMENT

 

Item 1. Description of Registrant’s Securities to be Registered.

 

Interpace Biosciences, Inc. (the “Company”) hereby incorporates by reference herein the description of its common stock, par value $0.01, to be registered hereunder, set forth under the heading “Description of Registrant’s Securities” in Exhibit 4.1 to the Company’s Registration Statement on Form S-1, as amended (File No. 333-299123), originally filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”) on September 25, 2026, which information shall be deemed to be incorporated herein by reference.

 

Item 2. Exhibits.

 

Pursuant to the Instructions as to Exhibits for Form 8-A, no exhibits are required to be filed because no other securities of the Company are registered on The Nasdaq Stock Market LLC, and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

 

 

SIGNATURES

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

 

Date: November 5, 2026	Interpace Biosciences, Inc.
	By:	/s/ Thomas W. Burnell
	Name:	Thomas W. Burnell
	Title:	Chief Executive Officer

 

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Polaris Renewable Energy Declares Quarterly Dividend
• Pflugerville's Quiet Rise: Chips, Aerospace and a 'Fit-Over-Force' Playbook
• STAK Energy Signs Long-Term Agreement to Bring North Slope Natural Gas to Market